Blogs
Healthcare and Medtech Research Reports
Apr 10, 2026
Summary Three drugs that have been approved for PV include JAKAFI/JAKAVI (ruxolitinib), BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), and PEGASYS (peginterferon alfa-2a). JAKAFI and BESREMi are approved in the US, Europe, and Japan, while PEGASYS is approved only in Europe. JAKAFI is nearing its pat...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper